Skip to content

Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra

Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00159848
Enrollment
8000
Registered
2005-09-12
Start date
2003-09-30
Completion date
2003-09-30
Last updated
2013-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impotence

Brief summary

This study will demonstrate if a treatment optimization program has an impact on the satisfaction with Viagra treatment in men with erectile dysfunction

Interventions

BEHAVIORALTreatment Optimization Program (educational material)

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male subjects above age of majority for whom sildenafil is prescribed for the first time within the usual practice of medicine

Exclusion criteria

* Male subjects who have used any ED medical treatments over the last month, with the exception of testosterone and/or herbal therapies * Subjects who do not have the possibility of viewing the video either through a computer, VCR or a DVD

Design outcomes

Primary

MeasureTime frame
Assess the impact of a sildenafil educational program versus usual care on subjects' satisfaction regarding their management of ED with sildenafil as assessed through the validated EDITS questionnnaire after 3 months of treatment

Secondary

MeasureTime frame
Describe the relationship between the administration of an educational program and the effectiveness of sildenafil; Evaluate the educational program as a tool to help physicians in their management of ED; Estimate the intracluster correlation coefficient

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026